(Q83156270)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22208547%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

title

Technological and behavioral strategies to reduce treatment burden and improve adherence to inhaled antibiotics in cystic fibrosis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22208547%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

1 reference

David E Geller

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22208547%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Susan Madge

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22208547%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

publication date

1 December 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22208547%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22208547%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

volume

105 Suppl 2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22208547%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

page(s)

S24-31

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22208547%20AND%20SRC:MED&resulttype=core&format=json

Pathophysiology and Management of Pulmonary Infections in Cystic Fibrosis

19 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970024-5

7 January 2021

The changing microbial epidemiology in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970024-5

7 January 2021

Clinical significance of microbial infection and adaptation in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970024-5

7 January 2021

Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health.

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970024-5

7 January 2021

Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: A European consensus

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970024-5

7 January 2021

Shifting patterns of inhaled antibiotic use in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970024-5

7 January 2021

Aerosol antibiotics in cystic fibrosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970024-5

7 January 2021

High treatment burden in adults with cystic fibrosis: challenges to disease self-management

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970024-5

7 January 2021

Variations in patients' adherence to medical recommendations: a quantitative review of 50 years of research

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970024-5

7 January 2021

Treatment compliance in children and adults with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970024-5

7 January 2021

Medical compliance and coping with cystic fibrosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970024-5

7 January 2021

Determinants of adherence in adults with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970024-5

7 January 2021

Longitudinal association between medication adherence and lung health in people with cystic fibrosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970024-5

7 January 2021

Noncompliance and treatment failure in children with asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970024-5

7 January 2021

Adherence with tobramycin inhaled solution and health care utilization

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970024-5

7 January 2021

In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970024-5

7 January 2021

Efficacy of aerosolized tobramycin in patients with cystic fibrosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970024-5

7 January 2021

A formulation of aerosolized tobramycin (Bramitob) in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection: a double-blind, placebo-controlled, multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970024-5

7 January 2021

Rapid pulmonary delivery of inhaled tobramycin for Pseudomonas infection in cystic fibrosis: a pilot project

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970024-5

7 January 2021

Pharmacokinetic and pharmacodynamic evaluation of liposomal amikacin for inhalation in cystic fibrosis patients with chronic pseudomonal infection

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970024-5

7 January 2021

Dry powder inhalation of colistin in cystic fibrosis patients: a single dose pilot study.

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970024-5

7 January 2021

Development of an inhaled dry-powder formulation of tobramycin using PulmoSphere™ technology

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970024-5

7 January 2021

Inhalation of a dry powder tobramycin PulmoSphere formulation in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970024-5

7 January 2021

Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970024-5

7 January 2021

Tobramycin inhalation powder for P. aeruginosa infection in cystic fibrosis: the EVOLVE trial

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970024-5

7 January 2021

Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970024-5

7 January 2021

Effect of dry powder inhaler resistance on the inspiratory flow rates and volumes of cystic fibrosis patients of six years and older.

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970024-5

7 January 2021

Inhalable antibiotic delivery using a dry powder co-delivering recombinant deoxyribonuclease and ciprofloxacin for treatment of cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970024-5

7 January 2021

Microbiology, safety, and pharmacokinetics of aztreonam lysinate for inhalation in patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970024-5

7 January 2021

Levofloxacin inhalation solution (MP-376) in patients with cystic fibrosis with Pseudomonas aeruginosa

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970024-5

7 January 2021

Pharmacokinetics and safety of tobramycin administered by the PARI eFlow rapid nebulizer in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970024-5

7 January 2021

Lung deposition of inhaled tobramycin with eFlow rapid/LC Plus jet nebuliser in healthy and cystic fibrosis subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970024-5

7 January 2021

The Adaptive Aerosol Delivery (AAD) technology: Past, present, and future

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970024-5

7 January 2021

Total deposition of therapeutic particles during spontaneous and controlled inhalations

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970024-5

7 January 2021

A randomised controlled trial of breathing modes for adaptive aerosol delivery in children with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970024-5

7 January 2021

Controlled inhalation of aerosolised therapeutics

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970024-5

7 January 2021

Adherence monitoring in drug delivery

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970024-5

7 January 2021

Open adherence monitoring using routine data download from an adaptive aerosol delivery nebuliser in children with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970024-5

7 January 2021

Perspective In Parental Coping With A Chronically Ill Child: The Case Of Cystic Fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970024-5

7 January 2021

Psychological and educational factors: better predictors of work status than FEV1 in adults with cystic fibrosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970024-5

7 January 2021

Child and parent perceptions of monitoring in chronic illness management: a qualitative study

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970024-5

7 January 2021

Identifying barriers to treatment adherence and related attitudinal patterns in adolescents with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970024-5

7 January 2021

Intentional and unintentional medication non-adherence: a comprehensive framework for clinical research and practice? A discussion paper

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970024-5

7 January 2021

Barriers to treatment adherence for children with cystic fibrosis and asthma: what gets in the way?

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970024-5

7 January 2021

Different perceptions of disease severity and self care between patients with cystic fibrosis, their close companions, and physician

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970024-5

7 January 2021

Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: poor adherence and the need to address it

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970024-5

7 January 2021

Adherence intervention research: what have we learned and what do we do next?

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970024-5

7 January 2021

Measurement of children's asthma medication adherence by self report, mother report, canister weight, and Doser CT.

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970024-5

7 January 2021

Accurate assessment of adherence: self-report and clinician report vs electronic monitoring of nebulizers.

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970024-5

7 January 2021

Cost-effectiveness of adherence-enhancing interventions: a quality assessment of the evidence

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970024-5

7 January 2021

Health policy, patient-centred care and clinical ethics

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970024-5

7 January 2021

Adherence and competence assessment in studies of CBT for psychosis: current status and future directions.

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970024-5

7 January 2021

Personal construct psychology: a theory to help understand professional development, a philosophy to support it.

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2811%2970024-5

7 January 2021

10.1016/S0954-6111(11)70024-5

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22208547%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

1 reference